Shanghai, China, March 4, 2024 – Asieris Pharmaceuticals (Stock Code: 688176.SH), a global biopharmaceutical leader in the discovery, development, and commercialization of innovative drugs for genitourinary tumors and related diseases announced that the international multicenter Phase III clinical study data of its non-surgical treatment for cervical HSIL (high grade squamous intraepithelial lesion) product APL-1702, will be presented for the first time as an oral presentation at the EUROGIN (European Research Organization on Genital Infection and Neoplasia) Congress held in Stockholm, Europe, on March 16, 2024.
Dr. Med. Peter Hillemanns
Dr.Peter Hillemann, Director of the Clinic for Gynaecology and Obstetrics, Director of the Claudia von Schilling Cancer Center (CCC Hannover), and Deputy Spokesman of the Comprehensive Cancer Center Lower Saxony at Hannover Medical School, will be the speaker.
About Asieris
Founded in March 2010, Asieris Pharmaceuticals (Stock Code: 688176.SH) is a global biopharmaceutical company committed to the discovery, development, and commercialization of innovative drugs for the treatment of genitourinary tumors and related diseases. Our mission is to enhance human health and uphold patient dignity. We aspire to be a global pharmaceutical leader, integrating research and development (R&D), manufacturing, and commercialization to deliver top-tier, integrated diagnostic and treatment solutions for patients both in China and around the world.
Asieris has been advancing its proprietary R&D platform and core technologies, pioneering new mechanisms of action, and conducting efficient screening and evaluation of drug candidates. With a robust in-house R&D system and a wealth of expertise in global drug development, we are dedicated to introducing first-in-class drugs and innovative products, addressing significant unmet medical needs in our areas of specialization.
In our pursuit of excellence in treating genitourinary diseases, Asieris actively enhances its pipeline through proprietary R&D endeavors and strategic partnerships. We remain at the forefront of emerging technologies and therapeutic advances. Our approach is both proactive and forward-thinking, focusing on identifying and addressing unmet clinical needs. We aim to develop an exceptional portfolio encompassing both diagnosis and treatment, striving to improve the lives of more patients in China and across the globe.
